Evidence map›Paper›PMID 27303748›Full record

ArticlemSphere

Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1.

Karl W Boehme, Mine' Ikizler, Jason A Iskarpatyoti, J Denise Wetzel, Jordan Willis, James E Crowe, Celia C LaBranche, David C Montefiori, Gregory J Wilson, Terence S Dermody

Open access · goldAbstract read
In one paragraph

Article in mSphere. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Karl W BoehmeDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Mine' IkizlerDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jason A IskarpatyotiDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
J Denise WetzelDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jordan WillisDepartment of Chemistry, Vanderbilt University, Nashville, Tennessee, USA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
James E CroweDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Celia C LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA; Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA; Laboratory for AIDS Vaccine Research and Development, Duke University Medical Center, Durham, North Carolina, USA.
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA; Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA; Laboratory for AIDS Vaccine Research and Development, Duke University Medical Center, Durham, North Carolina, USA.
Gregory J WilsonDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Terence S DermodyDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Elizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Vanderbilt University Medical Center · USDuke Medical Center · USVanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
Clonal Analysis of the Human B Cell Response to HIVU01AI078407 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E · 2008 to 2012
$3.9M
Oral Reovirus-Based Vaccines for Prevention of HIV-1 DiseaseR21AI091537 · NIAID · VANDERBILT UNIVERSITY · PI DERMODY, TERENCE S. · 2011 to 2012
$423k
NCI NIH HHS P30 CA068485NIAID NIH HHS R21 AI091537NIAID NIH HHS U01 AI078407NIDDK NIH HHS P30 DK020593
6 · The paper itself

Abstract

The gp41 membrane-proximal external region (MPER) is a target for broadly neutralizing antibody responses against human immunodeficiency virus type 1 (HIV-1). However, replication-defective virus vaccines currently under evaluation in clinical trials do not efficiently elicit MPER-specific antibodies. Structural modeling suggests that the MPER forms an α-helical coiled coil that is required for function and immunogenicity. To maintain the native MPER conformation, we used reverse genetics to engineer replication-competent reovirus vectors that displayed MPER sequences in the α-helical coiled-coil tail domain of viral attachment protein σ1. Sequences in reovirus strain type 1 Lang (T1L) σ1 were exchanged with sequences encoding HIV-1 strain Ba-L MPER epitope 2F5 or the entire MPER. Individual 2F5 or MPER substitutions were introduced at virion-proximal or virion-distal sites in the σ1 tail. Recombinant reoviruses containing heterologous HIV-1 sequences were viable and produced progeny yields comparable to those with wild-type virus. HIV-1 sequences were retained following 10 serial passages in cell culture, indicating that the substitutions were genetically stable. Recombinant viruses engineered to display the 2F5 epitope or full-length MPER in σ1 were recognized by purified 2F5 antibody. Inoculation of mice with 2F5-containing vectors or rabbits with 2F5- or MPER-containing vectors elicited anti-reovirus antibodies, but HIV-1-specific antibodies were not detected. Together, these findings indicate that heterologous sequences that form α-helices can functionally replace native sequences in the α-helical tail domain of reovirus attachment protein σ1. However, although these vectors retain native antigenicity, they were not immunogenic, illustrating the difficulty of experimentally inducing immune responses to this essential region of HIV-1. IMPORTANCE Vaccines to protect against HIV-1, the causative agent of AIDS, are not approved for use. Antibodies that neutralize genetically diverse strains of HIV-1 bind to discrete regions of the envelope glycoproteins, including the gp41 MPER. We engineered recombinant reoviruses that displayed MPER epitopes in attachment protein σ1 (REO-MPER vectors). The REO-MPER vectors replicated with wild-type efficiency, were genetically stable, and retained native antigenicity. However, we did not detect HIV-1-specific immune responses following inoculation of the REO-MPER vectors into small animals. This work provides proof of principle for engineering reovirus to express antigenic epitopes and illustrates the difficulty in eliciting MPER-specific immune responses.

Indexed as

human immunodeficiency virusimmunizationlive vector vaccinesneutralizing antibodiesreovirus

Identifiers

PMID27303748
PMCPMC4888892
OpenAlexW2407142948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.